Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada

Ads

You May Also Like

RedBrick Releases Results of its Person-First Approach to Chronic Condition Prevention and Management

MINNEAPOLIS, June 8, 2016 (GLOBE NEWSWIRE) -- RedBrick Health, a leading provider of technology-enabled ...

Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial  

NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional ...

ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting

SINGAPORE, Sept. 21, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical ...